Overview
Myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. It occurs when the immune system mistakenly attacks the nicotinic acetylcholine receptors of muscle fibers, which prevents the release of acetylcholine, a neurotransmitter needed to activate muscles. Myasthenia gravis affects up to 20 in every 100,000 people worldwide, and is more visible in females. Although the cause of myasthenia gravis is unknown, treatments such as medications, surgery, and plasmapheresis are available to help improve and manage the symptoms, including muscle weakness, blurry vision, and difficulty speaking, eating, and breathing. These treatments have been effective in improving the quality of life for many people with myasthenia gravis.
Research published in this journal
12 peer-reviewed articles, ranked by relevance. Each links to its DOI.
How this research is being cited
The 12 articles above have been cited 41 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2026 · The Nerve
-
2025 · Journal of Medicine, University of Santo Tomas
-
2024 · Journal of Clinical Medicine of Kazakhstan
-
2024 · Journal of Clinical Medicine of Kazakhstan
-
Marcello Benevento et al. · 2023 · Egyptian Journal of Forensic Sciences
-
2022 · Eastern Ukrainian Medical Journal
-
2022 · Eastern Ukrainian Medical Journal
-
2022 · Current Applied Science and Technology
A sample of recent works citing this journal's research on Myasthenia Gravis, linking to each citing work.